Express Pharma

NOVEMBER 30, 2023

If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades Karuna Therapeutics has announced that U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. Rishi Kakar, M.D.,

96

96

STAT

JANUARY 3, 2023

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Last year, a novel combination pill developed by Karuna Therapeutics reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage clinical trial.

246

246

European Pharmaceutical Review

MARCH 14, 2024

Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) have agreed a new partnership, which could result in the development of a new schizophrenia treatment targeting GPR52. HTL0048149 began first-in-human clinical trials in 2023, according to an announcement by Sosei in July 2023.

80

80

Pharmacy Times

JUNE 9, 2023

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

72

72

European Pharmaceutical Review

DECEMBER 22, 2023

The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. The drug is also undergoing trials both for adjunctive therapy to existing standard of care agents in schizophrenia and for the treatment of psychosis in patients with Alzheimer’s disease.

Drug Development 96

Drug Development 96

Pharmacy Times

APRIL 7, 2024

Potential adjunctive and novel treatment options based on a patient's specific symptoms and clinical factors are being explored to treat treatment-resistant schizophrenia

55

55

Pharmaceutical Technology

JULY 29, 2022

Schizophrenia Awareness Day, marked on 25 July, is a national observance that aims to raise awareness about this mental illness. Schizophrenia is a chronic brain disorder that affects a person’s ability to function, such as thinking and feeling. The other top sponsors can be seen in Figure 1.

98

98

Pharmafile

JANUARY 3, 2023

Published date: 03/01/2023.

52

52

European Pharmaceutical Review

DECEMBER 8, 2023

Cerevel’s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease, and mood disorders. The drug has shown promising efficacy and safety in a Phase Ib study for schizophrenia.

97

97

STAT

DECEMBER 7, 2023

 With this latest deal, AbbVie will acquire several clinical-stage molecules for Parkinson’s, schizophrenia, and epilepsy, among other disorders, many of which previously belonged to one of its biggest rivals. Continue to STAT+ to read the full story…

Drug Pricing 258

Drug Pricing 258

Pharmacy Times

JUNE 8, 2023

The estimated cost burden of schizophrenia is more than $150 billion, consisting of direct treatment cost and lost productivity.

49

49

Pharmaceutical Business Review

NOVEMBER 30, 2023

Schizophrenia is a long-lasting mental illness that can significantly affect a person’s thoughts, emotions, and behaviours. KarXT (xanomeline-trospium) is an investigational muscarinic antipsychotic under development to treat schizophrenia and psychosis related to Alzheimer’s disease. million affected in the US.

59

59

Pharmaceutical Commerce

NOVEMBER 29, 2023

In clinical trials, KarXT (xanomeline-trospium) demonstrated a combination of strong tolerability and clinically meaningful symptom reduction in adult patients with schizophrenia.

52

52

European Pharmaceutical Review

NOVEMBER 25, 2022

If approved, paliperidone palmitate extended-release injectable suspension (LY03010) is primed as a favourable option to treat schizophrenia, due to reduced dosage requirement of a once-a-month, yet it risks being hidden in a crowded long-acting injectable (LAI) market, GlobalData warns. percent of the US schizophrenia market in 2031.

Dosage 101

Dosage Labelling 101

STAT

DECEMBER 22, 2023

Food and Drug Administration is reviewing for treating schizophrenia. Drugmakers that normally try to sell drugs as soon as possible are suspending clinical trials and shifting timelines. The antipsychotic drug Amplify was once a blockbuster product for Bristol until the entry of generic competition.

262

262

Pharmacy Times

SEPTEMBER 7, 2022

The mainstay of treatment for schizophrenia and schizoaffective disorder includes antipsychotics.

52

52

Med Ed 101

JUNE 4, 2023

Originally approved as an atypical antipsychotic used for schizophrenia, or an adjunct therapy for major depressive disorder, Rexulti finds itself alone as the only medication for this indication. Earlier this month the FDA approved Rexulti (Brexpiprazole) for the treatment of agitation in patients with dementia due to Alzheimer’s.

98

98

Pharmaceutical Technology

NOVEMBER 14, 2023

Teva Pharmaceuticals and Royalty Pharma have partnered on a clinical research programme for olanzapine LAI (TEV-‘749), for schizophrenia.

52

52

Pharmafile

DECEMBER 7, 2023

This acquisition includes Cerevel’s neuroscience pipeline of various clinical-stage and preclinical candidates with potential indications across multiple disease areas, such as schizophrenia, Parkinson’s disease (PD) and mood disorders.

69

69

Pharmaceutical Technology

MARCH 18, 2024

Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Schizophrenia.

40

40

PharmExec

FEBRUARY 28, 2024

Agency identified several clinical deficiencies in the study, including insufficient evidence for roluperidone in the treatment of the negative symptoms associated with schizophrenia.

40

40

Pharmaceutical Technology

MAY 1, 2023

Teva Pharmaceuticals and MedinCell have received approval from the US Food and Drug Administration (FDA) for Uzedy (risperidone) extended-release injectable suspension to treat adult patients with schizophrenia, a chronic, progressive, and severely debilitating mental health disorder.

75

75

pharmaphorum

SEPTEMBER 1, 2021

One of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson’s pharma unit Janssen is trumpeting a new version of its Invega drug that could solve that problem. ” The post FDA clears J&J’s twice-yearly Invega for schizophrenia appeared first on. .

111

111

pharmaphorum

JANUARY 3, 2023

Encouraged by new data, Newron Pharmaceuticals has said it will start a registration study of would-be blockbuster evenamide in treatment-resistant schizophrenia (TRS) later this year. The post Newron says pivotal treatment-resistant schizophrenia trial is a go appeared first on.

Labelling 104

Labelling Drug Development 104

Pharmaceutical Technology

AUGUST 12, 2022

In June this year, it was announced that the US Food and Drug Administration (FDA) had granted UK-based OxfordVR a breakthrough device designation for its gameChangeVR treatment to deliver immersive cognitive behaviour therapy (CBT) to people suffering from schizophrenia and other mental illnesses. million people in the UK and 2.7

141

141

Pharmaceutical Technology

JULY 28, 2022

Discontinuation or non-adherence to antipsychotic treatment is the most common cause of relapse in patients diagnosed with schizophrenia. Despite the benefits of these products, resistance surrounding the use of LAIs in schizophrenia remains, resulting in lower-than-anticipated uptake.

98

98

pharmaphorum

AUGUST 6, 2021

Patient enrollment is a common issue across many therapeutic areas in clinical research. Psychiatric disorders have historically had great difficulty onboarding and retaining patients for clinical trials. In terms of poor enrolment, clinical trials investigating psychotic disorders like schizophrenia face a particular dilemma. .

Hospitals 104

Hospitals Communication 104

pharmaphorum

DECEMBER 20, 2022

Boehringer Ingelheim (BI) and Click Therapeutics have announced they are expanding their collaboration to develop and commercialise a second prescription-based digital therapeutic (PDT) that will provide additional treatment options to those living with schizophrenia. Schizophrenia is one of the 15 leading causes of disability worldwide.

52

52

Pharmaceutical Technology

OCTOBER 27, 2023

Zagociguat is under clinical development by Tisento Therapeutics and currently in Phase I for Schizophrenia.

52

52

pharmaphorum

AUGUST 8, 2022

Karuna Therapeutics has unveiled positive topline results from its phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia. The post Karuna Therapeutics scores phase 3 win for schizophrenia therapy KarXT appeared first on.

52

52

pharmaphorum

SEPTEMBER 15, 2020

Boehringer Ingelheim has signed a $500 million contract with Click Therapeutics to co-develop and market a digital treatment for patients with schizophrenia. The companies gave little away about CT-155, which is listed on Click’s website as being in the research phase before clinical trials have begun.

99

99

Pharmacy Times

JUNE 13, 2023

The ease of administration with new agents for schizophrenia via an injection is advantageous because this patient population is commonly agitated and difficult to administer oral medications to.

26

26

pharmaphorum

DECEMBER 17, 2020

This includes CAD-9303, a NMDAr positive allosteric modulator that could be used to treat schizophrenia, and MIJ-821, a NMDAr negative allosteric modulator for depression that was licensed to Novartis in 2015. With the acquisition of Cambridge, Massachusetts-based Cadent, Novartis gains rights to a portfolio of neurology drugs.

97

97

Med Ed 101

FEBRUARY 3, 2021

Here’s a case scenario where the clinical outcome may have hinged on taking ziprasidone with or without food. KD is a 33-year-old male who was diagnosed with schizophrenia. of schizophrenia. Olanzapine led to a quick uptick […].

40

40

European Pharmaceutical Review

JANUARY 5, 2024

Utilising an add-on therapy for treatment-resistant schizophrenia (TRS) Newron Pharmaceuticals SPA has reported significant final, one-year results from its clinical trial 014/015, evaluating evenamide as an add-on therapy to antipsychotics in treatment-resistant schizophrenia (TRS).

Labelling 102

Labelling 102

Pharmafile

MARCH 28, 2023

New data suggestive of clinically important response in TRS patients read more

52

52

pharmaphorum

JUNE 30, 2021

Shares in Pfizer spinout Cerevel Therapeutics have more than doubled after it reported positive early-stage results with CVL-231, a drug for schizophrenia that it thinks could have a clear side-effect profile than current therapies. The post Cerevel soars on first data for muscarinic schizophrenia drug appeared first on.

Drug Development 59

Drug Development 59